13/03/2026 Novartis announced FDA approval of secukinumab for pediatric patients with moderate to severe HS Novartis announced FDA approval of secukinumab for pediatric patients with moderate to severe HS ( Ref ) Novartis announced that the US FDA had approved Cosentyx® (secukinumab; anti-IL-17A) for the treatment of pediatric patients aged 12 years and older with moderate to severe hidradenitis suppurativa (HS) The use of Cosentyx in patients aged 12 years and older with mod

12/02/2026 The European Commission approved inebilizumab for the treatment of generalized myasthenia gravis The European Commission approved inebilizumab for the treatment of generalized myasthenia gravis ( Ref ) The European Commission approved Amgen’s Uplizna®(inebilizumab; anti-CD19 mAb) as an add-on treatment to standard therapy for adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (M